RENEE FONTAINE: Open Payments
NPI 1740988666 · STAMFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,140 in 68 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $323 · 2025 $2,140
Food & beverage: $2,140
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $641 |
| Janssen Pharmaceuticals, Inc | 11 | $455 |
| Teva Pharmaceuticals USA, Inc. | 7 | $236 |
| ABBVIE INC. | 12 | $208 |
| Otsuka America Pharmaceutical, Inc. | 2 | $149 |
| Neurocrine BioSciences, Inc. | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| Supernus Pharmaceuticals, Inc. | 3 | $80 |
| Corium, LLC | 4 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
Products named: CAPLYTA, SPRAVATO, AUSTEDO XR, VRAYLAR, REXULTI, INGREZZA, TRINTELLIX, Qelbree.
Industry payments across CT — which companies pay providers there.
